-+ 0.00%
-+ 0.00%
-+ 0.00%

Avacta Achieves Clinical Proof of Mechanism for the Next Generation of pre|CISION® Medicines with AVA6103 (FAP-Exd) in the Phase 1 FOCUS-01 Trial

Barchart·09/16/2026 10:00:00
Listen to the news

LONDON and PHILADELPHIA, Sept. 16, 2026 (GLOBE NEWSWIRE) -- Avacta Therapeutics (AIM: AVCT), a life sciences company developing innovative, targeted oncology drugs, announces today that it has achieved clinical proof of mechanism for AVA6103, its next-generation controlled-release pre|CISION® peptide-drug conjugate (PDC) platform in the ongoing phase 1 FOCUS-01 trial.

Read more at globenewswire.com

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.